Renal safety of amikacin compared with ceftriaxone in patients treated for urinary tract infection: an observational cohort study.

Authors

Iris Zohar, Dvir Melloul, Baruch Satra-Shenes, Orna Schwartz, Debby Ben David, Yasmin Maor

Published in

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Aug 06, 2026. Epub Aug 06, 2026.

Abstract

Aminoglycosides are broad-spectrum antibiotics commonly used as monotherapy for urinary tract infections (UTIs). However, their use is often limited by concerns regarding nephrotoxicity. We compared the renal safety of amikacin with ceftriaxone in patients treated for UTI with or without bloodstream infection.
We conducted a single-center retrospective cohort study including adult patients hospitalized between April 2018 and March 2022 who received amikacin or ceftriaxone for UTI for 3-10 days. Patients were matched 1:1 according to age, duration of therapy, and baseline renal function. The primary outcome was acute kidney injury (AKI), defined according to KDIGO criteria. Analyses included Kaplan-Meier time-to-event analysis, propensity score-adjusted Cox regression, and multivariable logistic regression. Alternative etiologies for AKI were also assessed.
A total of 138 matched pairs were included. Overall, 15 patients (5.4%) developed AKI: 9 (6.5%) in the amikacin group and 6 (4.3%) in the ceftriaxone group (P = 0.597), and Kaplan-Meier analysis likewise showed no difference between groups (log-rank P = 0.962). In propensity score-adjusted analysis of the total cohort, amikacin was not associated with increased risk of AKI (aHR 1.305, 95% CI 0.448-3.802, P = 0.626). Independent risk factors for AKI included institutional residence, higher Charlson comorbidity index, and bloodstream infection. Most AKI cases were mild and had alternative explanations.
In this matched cohort, amikacin was not associated with a higher risk of AKI compared with ceftriaxone. These findings suggest that, in selected patients, amikacin may represent a safe carbapenem-sparing option. Further studies are needed to confirm these findings.

PMID:
42560604
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.